A Phase 2 interventional study of Tocilizumab (Actemra®) and Dexamethasone in Acute Hypoxemic Respiratory Failure, sponsored by Lorenzo delSorbo. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Lorenzo delSorbo · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Respiratory Insufficiency with a site in Canada — 24 open to participants now, 29 under way, 1 of them phase 3. Respiratory Insufficiency · Canada.
Among the 94 studies in Respiratory Insufficiency with a site in Canada, this one is the 24th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 19 of the 28 other live ones, and was the 92nd registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →24 of the 94 studies in Respiratory Insufficiency with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
Laval University · Sites in Canada
Ages 18+
Laval University · Sites in Canada
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 12 · Phase 4 1
First in 1995; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 31 across the 66 interventional studies, 118 across the 28 observational. Of the 54 that completed or were terminated, 5 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 94 have an industry lead sponsor. The 10 most frequent:
Lorenzo delSorbo is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Lorenzo delSorbo has 2 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
11 of the studies in Respiratory Insufficiency with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07518862University Health Network, TorontoHeart Rate VAriability as a MaRker for tItrATing hIgh flOw Nasal Cannula Therapy | 2026-11 |
| NCT04524585University Health Network, TorontoPartial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure | 2026-12-01 |
| NCT07359261University of AlbertaTranspulmonary Assessment for Individualized Lung Optimization in Obese Patients | 2026-12-31 |
| NCT07334379Lorenzo delSorboInterleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study | 2027-02-20 |
| NCT05440851University Health Network, TorontoPlatform of Randomized Adaptive Clinical Trials in Critical Illness | 2027-03-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 94 studies in Respiratory Insufficiency with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute hypoxemic respiratory failure (AHRF) happens when the lungs are unable to absorb enough oxygen. The bloodstream is deprived of oxygen which can eventually lead to more severe conditions like multi-organ failure (MOF) and death. AHRF accounts for over 30% of patients to critical care units, thus novel treatments are sorely needed. Research has shown that blood levels of the inflammatory biomarker Interleukin-6 (IL-6) may be a reliable marker for predicting which patients with AHRF will progress into requiring intensive care unit (ICU) admission, MOF, and eventually death. IL-6 levels were shown to reliably peak several days before MOF, ICU admission, and death. Thus, the investigators believe that by identifying patients before the peak of their IL-6 levels, they will be able to administer early treatment to prevent the patient's condition from worsening. The aim of this study is to test the feasibility of a treatment strategy for AHRF based on IL-6 measurement in patients who are admitted to hospital care with AHRF.
This study has two phases: 1) observational and 2) interventional.
In the observational phase 1, patients who meet the inclusion and a general exclusion criteria are eligible for participation. In the observational phase, patients will have their plasma IL-6 levels measured over 2 days. Patients' clinical condition will be observed till discharge or up to 28 days of admission, and data will be collected from their medical charts.
Patients participating in the observational phase 1 will be considered eligible to join the interventional phase 2 if: they are found to have elevated IL-6 levels, and they meet additional randomization exclusion criteria. In the interventional phase, patients will be randomized into 1 of 3 treatment groups: standard of care only, standard of care plus a single IV infusion of Tocilizumab, or standard of care plus treatment with oral Dexamethasone for 10 days. Patients' clinical condition will be observed till discharge or up to 28 days of admission, and data will be collected from their medical charts. A follow-up phone interview will be conducted 6 months of the end of the observation period.
Patients participating in the observational phase 1 who are not eligible to participate in the interventional phase 2 will continue in the observational phase 1 only. These patients will not be randomized to a group, receive any study medications, or be contacted for the 6-month follow-up.
The criteria were revised on the registry on Oct 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
General Exclusion:
Randomization Exclusion
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Routine care only
Routine care + single intravenous infusion of tocilizumab at a dose of 4mg/kg of body weight (up to a max 400mg).
Drug: Tocilizumab (Actemra®)
Routine care + a 10mg of oral dexamethasone per day for up to 10 days (or until hospital discharge).
Drug: Dexamethasone
Subjects randomized to the tocilizumab arm will receive a single intravenous (IV) infusion of tocilizumab, given over 1 hour. The tocilizumab will be given at a dosage of 4mg per kg of body weight, up to a maximum dose of 400 mg.
Subjects randomized to the dexamethasone arm will receive 6 mg of dexamethasone per day, for up to 10 days, or until discharged from the hospital. Dexamethasone will be given in tablet form orally (by mouth) or through an equivalent method.
To determine the potential recruitment rate
Time frame: From enrollment to completion of the study (in including the 6-month follow-up).
To assess the proportion of eligible patients who do not have daily IL-6 measurement
Time frame: Baseline (Day 0) to Day 2
To assess the proportion of eligible patients who are not randomized
Time frame: Baseline (Day 0) to Day 2
To determine the rate of adherence to the assigned treatment strategy and any cross-overs
Time frame: Baseline to end of 28-day observation period (or hospital discharge)
To estimate the time from hospital admission to randomization and initiation of the allocated treatment
Time frame: Baseline to Day 3
All cause 28-day mortality
Time frame: From enrollment to completion of the 28-day observation period (or hospital discharge).
Sequential Organ Failure Assessment (SOFA) score increase of ≥2 or death
The SOFA (Sequential Organ Failure Assessment) scale is used to assess a patient's organ function. The SOFA score is based on 6 different systems: respiratory, cardiovascular, hepatic, coagulation, renal, and neurological. Each system is given a score from 0 (best) to 4 (worst). Total SOFA score is calculated by adding the scores for each system, with a lower total SOFA scores generally denote better overall organ function.
Time frame: From enrollment to end of 28-day observation period (or hospital discharge).
Development of ARDS or death
Time frame: From enrollment to end of 28-day observation period (or hospital discharge).
ICU admission or death
Time frame: From enrollment to end of 6-month follow-up period.
Hospital length of stay
Time frame: From enrollment to end of 28-day observation period (or hospital discharge).
ICU length of stay
Time frame: From enrollment to end of 28-day observation period (or hospital discharge).
Need for invasive mechanical ventilation or death
Time frame: From enrollment to end of 28-day observation period (or hospital discharge).
Duration of invasive mechanical ventilation
Time frame: From enrollment to end of 28-day observation period (or hospital discharge).
Health related quality of life at 6 months assessed using the 36-Item Short Form Survey (SF-36)
The SF-36 is a 36-item survey that scores patients on eight health scales: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. The SF-36 is structured so higher scores on each scale generally denote a more favorable health outcome. It also includes a single item that provides an indication of perceived change in health.
Time frame: From enrollment to 6 months after the end of 28-day observation period (or hospital discharge)
Survival at 6 months
Time frame: From enrollment to end of 6-month follow-up period.
Complications of steroids or tocilizumab including
Complications including: Hypersensitivity or allergic reaction to tocilizumab, Nosocomial infections, Neuromuscular weakness, Gastrointestinal perforations.=, Hypernatremia (serum sodium \>150 mmol/L), Hyperglycemia (requiring new insulin or increased insulin dose), Hepatic dysfunction, Demyelinating disorders, Myocardial infarction or acute coronary syndrome, Malignancies, Stroke, New delirium, Neuromuscular weakness, Clinically significant gastrointestinal bleeding (requiring transfusion or endoscopy), Fetal and infant harm, and Death
Time frame: From enrollment to end of 28-day observation period (or hospital discharge).
To assess reasons why eligible patients are not randomized
In addition to primary outcome #3: To assess the proportion of eligible patients who are not randomized, the reasons why eligible patients are not randomized will also be recorded.
Time frame: Baseline (Day 0) to Day 2.
Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.
Of 30 phase 2 interventional studies under Respiratory Insufficiency, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 16 months is above that.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Feb 2027, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tocilizumab · Dexamethasone
Lorenzo delSorbo